Derek Maetzold, president and chief executive officer, Frank Stokes, chief financial officer, and other members of Castle’s executive leadership team will provide an overview of the Company’s long-term corporate strategy, growth plans, research and development initiatives and financial outlook.
In a recent study, patients diagnosed with melanoma and tested with DecisionDx-Melanoma had improved survival (27% improvement in melanoma-specific survival) compared to untested patients.
A live audio webcast of the company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx . A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.